Literature DB >> 31106483

Prescription opioid use patterns, use disorder diagnoses and addiction treatment receipt after the 2014 Medicaid expansion in Oregon.

Rachel Springer1, Miguel Marino1,2, Steffani R Bailey1, Heather Angier1, Jean P O'Malley1,3, Megan Hoopes3, Stephan Lindner2,4, Jennifer E DeVoe1,3, Nathalie Huguet1.   

Abstract

BACKGROUND/AIMS: Evidence suggests that Medicaid beneficiaries in the United States are prescribed opioids more frequently than are people who are privately insured, but little is known about opioid prescribing patterns among Medicaid enrollees who gained coverage via the Affordable Care Act Medicaid expansions. This study compared the prevalence of receipt of opioid prescriptions and opioid use disorder (OUD), along with time from OUD diagnosis to medication-assisted treatment (MAT) receipt between Oregon residents who had been continuously insured by Medicaid, were newly insured after Medicaid expansion in 2014 or returned to Medicaid coverage after expansion.
DESIGN: Cross-sectional study using inverse-propensity weights to adjust for differences among insurance groups.
SETTING: Oregon. PARTICIPANTS: A total of 225 295 Oregon Medicaid adult beneficiaries insured during 2014-15 and either: (1) newly enrolled, (2) returning in 2014 after a > 12-month gap or (3) continuously insured between 2013 and 2015. We excluded patients in hospice care or with cancer diagnoses. MEASUREMENTS: Any opioid-dispensed, chronic (> 90-days) and high-dose (> 90 daily morphine milligram equivalence) opioid use, documented OUD diagnosis and MAT receipt.
FINDINGS: Compared with the continuously insured, newly and returning insured enrollees were less likely to be dispensed opioids [newly: 42.3%, 95% confidence interval (CI) = 42.0-42.7%; returning: 49.3%, 95% CI = 48.8-49.7%; continuously: 52.5%, 95% CI = 52.0-53.0%], use opioids chronically (newly: 12.8%, 95% CI = 12.4-13.1%; returning: 11.9%, 95% CI = 11.5-12.3%, continuously: 15.8%, 95% CI = 15.4-16.2%), have OUD diagnoses (newly: 3.6%, 95% CI = 3.4-3.7%; returning: 3.9%, 95% CI = 3.8-4.1%, continuously: 4.7%, 95% CI = 4.5-4.9%) and receive MAT after OUD diagnosis [hazard ratio newly: 0.57, 95% CI = 0.53-0.61; hazard ratio returning: 0.60, 95% CI = 0.56-0.65 (ref: continuously)].
CONCLUSIONS: Residents of Oregon, United States who enrolled or re-enrolled in Medicaid health insurance after expansion of coverage in 2014 as a result of the Affordable Care Act were less likely than those already covered to receive opioids, use them chronically or receive medication-assisted treatment for opioid use disorder.
© 2019 Society for the Study of Addiction.

Entities:  

Keywords:  Affordable care act; Medicaid; medication-assisted treatment; opioid epidemic; opioid use disorder; prescribed opioid use

Year:  2019        PMID: 31106483      PMCID: PMC6731997          DOI: 10.1111/add.14667

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  23 in total

1.  A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002.

Authors:  Aaron M Gilson; Karen M Ryan; David E Joranson; June L Dahl
Journal:  J Pain Symptom Manage       Date:  2004-08       Impact factor: 3.612

Review 2.  Major increases in opioid analgesic abuse in the United States: concerns and strategies.

Authors:  Wilson M Compton; Nora D Volkow
Journal:  Drug Alcohol Depend       Date:  2005-07-14       Impact factor: 4.492

Review 3.  Treatment of cancer pain.

Authors:  Russell K Portenoy
Journal:  Lancet       Date:  2011-06-25       Impact factor: 79.321

4.  A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.

Authors:  Stacey C Sigmon; Kelly E Dunn; Kathryn Saulsgiver; Mollie E Patrick; Gary J Badger; Sarah H Heil; John R Brooklyn; Stephen T Higgins
Journal:  JAMA Psychiatry       Date:  2013-12       Impact factor: 21.596

5.  De facto long-term opioid therapy for noncancer pain.

Authors:  Michael Von Korff; Michael Von Korff; Kathleen Saunders; Gary Thomas Ray; Denise Boudreau; Cynthia Campbell; Joseph Merrill; Mark D Sullivan; Carolyn M Rutter; Michael J Silverberg; Caleb Banta-Green; Constance Weisner
Journal:  Clin J Pain       Date:  2008 Jul-Aug       Impact factor: 3.442

6.  Overdose deaths involving prescription opioids among Medicaid enrollees - Washington, 2004-2007.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-10-30       Impact factor: 17.586

7.  The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients.

Authors:  Mary E Charlson; Robert E Charlson; Janey C Peterson; Spyridon S Marinopoulos; William M Briggs; James P Hollenberg
Journal:  J Clin Epidemiol       Date:  2008-07-10       Impact factor: 6.437

8.  A tutorial on propensity score estimation for multiple treatments using generalized boosted models.

Authors:  Daniel F McCaffrey; Beth Ann Griffin; Daniel Almirall; Mary Ellen Slaughter; Rajeev Ramchand; Lane F Burgette
Journal:  Stat Med       Date:  2013-03-18       Impact factor: 2.373

Review 9.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

10.  Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.

Authors:  Paul J Fudala; T Peter Bridge; Susan Herbert; William O Williford; C Nora Chiang; Karen Jones; Joseph Collins; Dennis Raisch; Paul Casadonte; R Jeffrey Goldsmith; Walter Ling; Usha Malkerneker; Laura McNicholas; John Renner; Susan Stine; Donald Tusel
Journal:  N Engl J Med       Date:  2003-09-04       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.